Back to MPT Database

90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR]

A 90-day pod-type MPT IVR for pregnancy and HIV prevention that could reduce both the emergence of ARV-resistant HIV and the concern of potential increased risk of HIV transmission associated with use of progestin-only products.

Development Stage:

Preclinical – Early (Pre1)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Topical - Intravaginal Ring (IVR)

Mechanism of Action:

Ovulation inhibition (pregnancy); binding to HIV envelope glycoproteins to prevent entry of HIV into target cells (QGRFT).

Developer:

  • Oak Crest Institute of Science
  • Population Council

Funding:

  • Nat. Institute Allergy & Infect. Diseases (NIAID)
  • National Institutes of Health (NIH)

Funding Mechanism:

NIH: R01 (NIAID)

Active Ingredient(s):

  • Etonogestrel
  • Ethinyl Estradiol
  • QGriffithsin (QGRFT)

Product Indication(s):

  • HIV
  • Pregnancy

Back to MPT Database